Dapagliflozin for treating chronic heart failure with reduced ejection fraction

  • Technology appraisal guidance
  • TA679
  • Published: 
Download guidance (PDF)

2 Information about dapagliflozin

Marketing authorisation indication

2.1 Dapagliflozin (Forxiga, AstraZeneca) has a marketing authorisation 'for the treatment of symptomatic chronic heart failure with reduced ejection fraction'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price of dapagliflozin is £36.59 per 28‑tablet pack (excluding VAT; BNF online, accessed November 2020). The annual treatment cost is £476.98. Costs may vary in different settings because of negotiated procurement discounts.